Abstract
COVID-19 is associated with hypercoagulability and endothelial injury, which contribute to an increased risk of macro- and microvessel thrombosis, disease progression and death.[1][1] In a randomized controlled trial terminated early owing to lower than expected event rates, neither acetylsalicylic
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
